Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2022-04-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021. The content includes detailed descriptions of internal control scope, standards, defect identification, and remediation status. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document length is 4068 characters, which is relatively short but contains substantive content rather than just an announcement or certification. The nature of the report aligns with an Audit Report / Information (AR) category, as it deals with internal control evaluation and audit opinions on internal controls, which is typical for audit-related filings separate from the full annual report (10-K). Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2021
2022-04-29 Chinese
关于奥锐特药业股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 100% confidence The document is a specialized audit report titled "专项审计报告" related to non-operating fund occupation and other related party fund transactions for 奥锐特药业股份有限公司 for the year 2021. It includes detailed audit opinions, audit scope, and summary tables of fund occupation and related party transactions. The presence of audit firm details, signatures of certified public accountants, and references to regulatory guidelines confirms this is a standalone audit report. The document is 6752 characters long, which is sufficient to contain substantive audit content rather than just an announcement. It is not a full annual report (10-K) or interim report (IR) but a specific audit report on a particular issue. Therefore, the correct classification is Audit Report / Information (AR). FY 2021
2022-04-29 Chinese
奥锐特药业股份有限公司2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, and financial statements. It includes audited financial statements with signatures from company officers and auditors, and detailed financial metrics for the fiscal year ending December 31, 2021. The length of the document (15,000 characters) and the comprehensive content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-29 Chinese
奥锐特药业股份有限公司监事会议事规则（2022年修订）
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' for 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.). It details the procedures, rules, and governance structure for the supervisory board meetings, including meeting types, notification procedures, voting rules, record keeping, and responsibilities. There is no financial data, no report of financial results, no announcement of voting results, no management changes, no legal proceedings, no capital updates, and no other regulatory filings. The content is focused on internal governance rules related to the supervisory board, which fits the definition of Governance Information (CGR). The document is not an announcement but the actual rules text, so it is not RPA or RNS. The length is 2735 characters, which is relatively short but sufficient for a governance document. Therefore, the best classification is Governance Information (CGR).
2022-04-29 Chinese
奥锐特药业股份有限公司董事、监事、高级管理人员买卖公司股票管理办法
Director's Dealing Classification · 95% confidence The document is titled as a management method for the trading of company shares by directors, supervisors, and senior management personnel of 奥锐特药业股份有限公司. It details rules, responsibilities, and procedures related to insider trading, reporting, and disclosure obligations for these individuals. It does not contain financial statements, earnings data, or any report of financial performance. It is a governance-related document focusing on internal rules and compliance regarding insider share transactions. Therefore, it fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2022-04-29 Chinese
奥锐特药业股份有限公司2021年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度审计报告' which translates to '2021 Annual Audit Report'. It contains detailed audit opinions, audit basis, key audit matters, and extensive financial statements including consolidated and parent company balance sheets, profit statements, cash flow statements, and notes. The presence of audit opinions and detailed financial data indicates this is a standalone audit report rather than a full annual report or a simple announcement. The document length is substantial (15,000 characters), and it includes detailed audit procedures and findings, which are typical of an Audit Report / Information filing. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2021
2022-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.